Day: December 27, 2023

– Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed – – 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is Approximately 28 Weeks – – Median Overall Survival of Patients without GPS Immune Response was 9.0 Months vs. 27.8 Months for Patients with GPS-Specific Immune Response: a Three-fold or 208.3% Increase in Survival Time – NEW YORK, Dec. 27, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced follow-up clinical/immune-response data from...

Company Leverages its KULR ONE Design Solutions Platform for Initial Battery Safety Technology Order SAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, today announced it has received an initial purchase order from one of the world’s largest privately held space exploration companies (“Customer”) for enhanced battery safety testing solutions, using the Company’s KULR ONE Design Solutions (“K1-DS”) platform. The proprietary K1-DS platform incorporates the most comprehensive design and testing methodology for battery safety that includes: Internal Short Circuit (“ISC”) technology, Fractional Thermal Runaway Calorimetry (“FTRC”), bomb calorimetry, and impingement zone mapping,...

On 15 November 2023, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 14 of 14 November 2023. Under the programme Schouw & Co. will acquire shares for up to DKK 75 million during the period 15 November 2023 to 1 March 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 15/12/2023 48,900 535.27 26,174,899    Monday, 18 December 2023 2,000 543.80 1,087,600    Tuesday, 19 December 2023 1,800 544.68 980,424    Wednesday, 20 December 2023 1,900 544.91 1,035,329    Thursday, 21 December 2023 1,900 539.51 1,025,069    Friday,...

NEW YORK, Dec. 27, 2023 (GLOBE NEWSWIRE) — Society Pass Inc. (Nasdaq: SOPA) (“SoPa” or the “Company”), Southeast Asia’s (SEA) next generation, data-driven, loyalty, fintech and e-commerce ecosystem, announces that Litchfield Hills Research (“Litchfield Hills”) has initiated equity research coverage on SOPA. Click Here (on Society Pass website) to view the full Litchfield Hills Equity Research Report. Summary Points:• Investment Thesis: SOPA is a high-growth acquisitive internet services company offering advertising, travel, retail, telecom and fintech services in fast-growing SEA. Litchfield Hills forecasts positive EBITDA as SOPA shifts from its early growth strategy to a focus on profitability under its new CEO. • SEA Countries are Young and Booming and are Hottest Economies on the Planet: SEA market is the world’s fastest growing...